A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Golcadomide (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Tafasitamab (Primary) ; Tazemetostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
Most Recent Events
- 19 Nov 2024 According to a Bristol Myers Squibb media release, results from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California.
- 13 Jun 2024 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
- 03 Apr 2024 Planned number of patients changed from 387 to 438.